← Leaderboards
Sangeetha Srinivasan
Tambo, Inc.
$1,788,485
Attributed
$1,788,485
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $910.7K · FY2018–21$1M$750K$500K$250K$0
'18
'19
'20
'21
Funding mix
By agency
NIH$1,788,485 · 2
By mechanism
R44$1,488,608 · 1
R43$299,877 · 1
Top collaborators
No co-investigators on record.
Most similar at Tambo, Inc.
Same institution · by research overlap
- Nathan Yee$1,219,851
- Jose Mejia Oneto$1,429,073
Others in their field
Other Emerging Leaders on “Injectable”
- Yunda Huang · Fred Hutchinson Cancer Center$58,397,458
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Laura McNay · Leidos Biomedical Research, Inc.$15,147,252
- Manish Ishwar Shah · Baylor College Of Medicine$13,280,421
- Benjamin E Deverman · Broad Institute, Inc.$12,739,936
- Nikej Shah · Nirsum Laboratories, Inc.$12,506,430
Research focus
InjectablePharmaceutical PreparationsDoxorubicinImplantMaximum Tolerated DoseOperative Surgical ProceduresChemistryDoseDrug DevelopmentFormulationIn VivoLegal PatentMedicineNovel TherapeuticsAdverse EventCancer TherapyControlled ReleaseDosageAlginatesDrug Delivery SystemsDrug KineticsExcisionCyclooctenesProdrugs
Grant awards (3)
Material-guided delivery and local activation of bioorthogonal prodrugs$577,898
R44 · FY2021 · GM · contact PI
Material-guided delivery and local activation of bioorthogonal prodrugs$910,710
R44 · FY2020 · GM · contact PI
Material guided drug delivery for pediatric tumors using an implantable biomaterial and bio-orthogonal chemistry$299,877
R43 · FY2018 · HD · contact PI